Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Wellbutrin for Crohn's Disease
NCT00126373Phase 3Completed
- Sponsor
- Eric Altschuler, M.D.
- Start
- May 2005
- Primary completion
- Mar 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bupropion in Crohn's disease (2 arms), sponsored by Eric Altschuler, M.D. Primary endpoint: Number of patients with Crohn's disease activity index (CDAI) < 150 at 12 weeks. Started May 2005; status: completed.
02
Drugs
bupropion
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT00126373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00126373.